The hyaluronan synthase 1 (HAS-1) gene
encodes a plasma membrane protein that synthesizes
hyaluronan (HA), an extracellular
matrix molecule. Accumulating evidence
emphasizes the relevance of HA metabolism in
an increasing number of processes of clinical
interest, including abdominal aortic aneurysm
(AAA). The existence of aberrant splicing variants
of the HAS-1 gene could partly explain the
altered extracellular matrix architecture and
influence various biological functions, resulting
in progressive arterial wall failure in the
development of AAA. In the present study, we
assessed the hypothesis that HAS-1 genetic
833A/G polymorphism could be associated with
the risk of AAA by performing a case-control
association study, involving AAA patients and
healthy matched donors.
Aneurysm, genetics, hyaluronan synthase, SNP, susceptibility.
Chiara Armani, Cardiac Thoracic and Vascular Department, University of Pisa, via Paradisa 2, 56124 Pisa, Italy E-mail: firstname.lastname@example.org
Share this Article
Related Content In Cardiovascular Disease
Low-flow, Low-gradient Severe Aortic Stenosis: A Review
Heart International. 2023;17(1):Online ahead of journal publication
The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common causes worldwide.2 Population-wide trends in developed countries suggest a strong relationship between advanced age and incidence of […]
Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention
Heart International. 2022;16(2):105–11 DOI: https://doi.org/10.17925/HI.2022.16.2.105
In recent years, patients undergoing non-emergent percutaneous coronary intervention (PCI) procedures have become increasingly older, with a more significant comorbidity burden and complex coronary disease.1 Many of the patients who undergo elective or urgent PCI are surgical turndown patients, for whom PCI is the only revascularization option.2 For these high-risk patients, more interventionalists are opting for […]
Can Percutaneous Coronary Intervention Revive a Failing Heart?
Heart International. 2022;16(2):72–4 DOI: https://doi.org/10.17925/HI.2022.16.2.72
Percutaneous coronary intervention (PCI) has evolved considerably in both technique and technology since Andreas Grüntzig first intervened on a focal, proximal lesion in the left anterior descending artery in 1977.1 While this has resulted in increasingly complex anatomical subsets being treated, contemporary trials of PCI in patients with stable coronary artery disease (CAD) have continued to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!